Group
MET targeting TKI
Group Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Tyrosine Kinase Inhibitors (TKIs) |
| Mechanism of Action | MET inhibitor |
| Drugs in group | Capmatinib· Tepotinib |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Radiosensitizing in MET-dependent tumors (blocks RT-induced MET, ATR-CHK1-CDC25, PI3K/ERK); enhanced in p53-deficient cells, absent in MET–wild-type (Ramesh et al., International Journal of Radiation Oncology, Biology, Physics, 2024; Mikami et al., Molecular Cancer Research, 2015). Driver-restricted sensitization implies limited added normal-tissue adverse events in theory.
The data above refer to patients treated with MET targeting TKI as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.